钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂患者的ICU入院风险及相关死亡率:一项全地区回顾性队列研究
本研究为全地区回顾性队列研究,数据来自香港临床数据分析与报告系统,纳入2015年1月1日至2019年12月31日新处方SGLT2抑制剂或DPP-4抑制剂的成人2型糖尿病患者。经1:2倾向评分匹配后共纳入27,972例(SGLT2抑制剂10,308例 vs DPP-4抑制剂17,664例),中位随访2.9年。SGLT2抑制剂组ICU入院率更低(286例[2.8%] vs 645例[3.7%];HR 0.79;95%CI 0.69-0.91;p=0.001),全因死亡率更低(315例[3.1%] vs 1,327例[7.5%];HR 0.44;95%CI 0.38-0.49;p<0.001),脓毒症相关入院和死亡也更低。作者结论认为SGLT2抑制剂与较低的ICU入院率和全因死亡率独立相关。
要点
- SGLT2抑制剂组ICU入院286例(2.8%) vs DPP-4抑制剂组645例(3.7%),HR 0.79(95%CI 0.69-0.91),p=0.001。
- SGLT2抑制剂组全因死亡315例(3.1%) vs DPP-4抑制剂组1,327例(7.5%),HR 0.44(95%CI 0.38-0.49),p<0.001。
- 脓毒症入院SGLT2抑制剂组45例(0.4%) vs DPP-4抑制剂组134例(0.8%),p=0.001;脓毒症死亡59例(0.6%) vs 414例(2.3%),p<0.001。
- ICU入院时疾病严重程度按急性生理与慢性健康评分IV预测死亡风险在SGLT2抑制剂使用者中也更低。
- 匹配后人群平均年龄59±11岁,男性17,416例(62.3%),中位随访2.9年。
适用人群与场景
- 年龄≥18岁的成人2型糖尿病患者,于2015年1月1日至2019年12月31日期间新处方SGLT2抑制剂或DPP-4抑制剂。
- 数据来自香港全地区临床注册系统(临床数据分析与报告系统)。
研究设计与关键结果
- 研究类型:回顾性观察性研究(全地区回顾性队列),数据来自香港临床数据分析与报告系统。
- 经1:2倾向评分匹配后共纳入27,972例患者(SGLT2抑制剂10,308例 vs DPP-4抑制剂17,664例),平均年龄59±11岁,男性17,416例(62.3%),中位随访2.9年。
- 主要终点:SGLT2抑制剂组ICU入院286例(2.8%) vs DPP-4抑制剂组645例(3.7%),HR 0.79(95%CI 0.69-0.91),p=0.001。
- 全因死亡:SGLT2抑制剂组315例(3.1%) vs DPP-4抑制剂组1,327例(7.5%),HR 0.44(95%CI 0.38-0.49),p<0.001。
- 脓毒症入院:SGLT2抑制剂组45例(0.4%) vs DPP-4抑制剂组134例(0.8%),p=0.001;脓毒症死亡:SGLT2抑制剂组59例(0.6%) vs DPP-4抑制剂组414例(2.3%),p<0.001。
- ICU入院时疾病严重程度按急性生理与慢性健康评分IV预测死亡风险在SGLT2抑制剂使用者中也更低。
证据类型、等级与局限
- 证据类型:回顾性观察性研究(全地区回顾性队列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在成人2型糖尿病患者中,使用SGLT2抑制剂较DPP-4抑制剂与更低的ICU入院率、全因死亡率及脓毒症相关入院和死亡独立相关(HR 0.79、0.44等),作者结论认为SGLT2抑制剂与较低的ICU入院率和全因死亡率独立相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in reducing the occurrence rate of adverse cardiac and renal outcomes in patients with type 2 diabetes has been well described in randomized trials. Whether this benefit extends to patients at the most severe end of the disease spectrum requiring admission to the ICU remains to be examined.
DESIGN: Retrospective observational study.
SETTING: Data were obtained from a territory-wide clinical registry in Hong Kong (Clinical Data Analysis and Reporting System).
PATIENTS: All adult patients (age ≥ 18 yr) with type 2 diabetes and newly prescribed SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors between January 1, 2015, and December 31, 2019.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: After 1:2 propensity score matching, a total of 27,972 patients (10,308 SGLT2 inhibitors vs 17,664 DPP-4 inhibitors) were included in the final analysis. The mean age was 59 ± 11 years, and 17,416 (62.3%) were male. The median follow-up period was 2.9 years. The use of SGLT2 inhibitors was associated with decreased ICU admission (286 [2.8%] vs 645 [3.7%]; hazard ratio [HR], 0.79; 95% CI, 0.69-0.91; p = 0.001) and lower risks of all-cause mortality (315 [3.1%] vs 1,327 [7.5%]; HR, 0.44; 95% CI, 0.38-0.49; p < 0.001), compared with DPP-4 inhibitors. The severity of illness upon ICU admission by Acute Physiology and Chronic Health Evaluation IV-predicted risk of death was also lower in SGLT2 inhibitors users. Admissions and mortality due to sepsis were lower in SGLT2 inhibitor users compared with DPP-4 inhibitor users (admissions for sepsis: 45 [0.4%] vs 134 [0.8%]; p = 0.001 and mortality: 59 [0.6%] vs 414 [2.3%]; p < 0.001, respectively).
CONCLUSIONS: In patients with type 2 diabetes, SGLT2 inhibitors were independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
参考来源
- Ng PY, Ng AK, Ip A, et al. Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Crit Care Med. 2023. PMID: 37026864. doi:10.1097/CCM.0000000000005869
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。